Fortrea acquires Worldwide Clinical Trials Early Phase
Analysis based on 6 articles · First reported Sep 02, 2026 · Last updated Sep 02, 2026
Fortrea Holdings Inc. (FTRE) announced a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in cash. The acquisition includes a 60,000 sq. ft. GLP-compliant bioanalytical laboratory in Austin, Texas, a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, and a biospecimen storage facility in Pflugerville, Texas. These facilities will integrate into Fortrea's Clinical Pharmacology Services business unit, adding large and small molecule bioanalytical capabilities and expanding its North American early-phase clinical research footprint. The deal supports Fortrea's end-to-end clinical development platform from first-in-human through Phase IV and post-approval studies. Worldwide Clinical Trials will continue to support existing and future Phase I studies through its broader capabilities, ensuring continuity during the transition. The transaction is subject to regulatory and license approvals. Barclays served as financial advisor to Fortrea, with Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo as legal counsel. BroadOak Partners advised Worldwide, with Greenberg Traurig as legal counsel. Fortrea's stock rose in pre-market trading following the announcement.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard